Sign-up for our newsletter

Publication

How to best manage glycemia and non-glycemia during the time of acute myocardial infarction.

Authors Hirsch IB, O'Brien KD Submitted By Kevin O'Brien on 10/31/2012 Status Published Journal Diabetes technology & therapeutics Year 2012 Date Published 6/1/2012 Volume : Pages 14 Suppl 1 : S22 - S32 PubMed Reference 22650221 Abstract Acute myocardial infarction (AMI) is common in patients with diabetes. Reasons for this are multifactorial, but all relate to a variety of maladaptive responses to acute hyperglycemia. Persistent hyperglycemia is associated with worse left ventricular function and higher mortality during AMI, but intervention data are far from clear. Although there is a theoretical basis for the use of glucose-insulin-potassium infusion during AMI, lack of outcome efficacy (and inability to reach glycemic targets) in recent randomized trials has resulted in little enthusiasm for this strategy. Based on the increasing understanding of the dangers of hypoglycemia, while at the same time appreciating the role of hyperglycemia in AMI patients, goal glucose levels of 140-180 mg/dL using an intravenous insulin infusion while not eating seem reasonable for most patients and hospital systems. Non-glycemic therapy for patients with diabetes and AMI has benefited from more conclusive data, as this population has greater morbidity and mortality than those without diabetes. For ST-elevation myocardial infarction (STEMI), reperfusion therapy with primary percutaneous coronary intervention or fibrinolysis, antithrombotic therapy to prevent acute stent thrombosis following percutaneous coronary intervention or rethrombosis following thrombolysis, and initiation of ß-blocker therapy are the current standard of care. Emergency coronary artery bypass graft surgery is reserved for the most critically ill. For those with non-STEMI, initial reperfusion therapy or fibrinolysis is not routinely indicated. Overall, there have been dramatic advances for the treatment of people with AMI and diabetes. The use of continuous glucose monitoring in this population may allow better ability to safely reach glycemic targets, which it is hoped will improve glycemic control.

Investigators with authorship
Name Institution Kevin O'Brien University of Washington

Complications
All Complications Bioinformatics Bone Cardiomyopathy Cardiovascular Gastro-Intestinal (GI) Nephropathy Neuropathy & Neurocognition Pediatric Endocrinology Retinopathy Uropathy Wound Healing